Does J3489 require prior authorization?

No, J3489 does not require prior authorization (high confidence). Code is covered without prior authorization.

What is the Medicare reimbursement rate for J3489?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

HCPCS/CPT

No Prior Auth Required

Code is covered without prior authorization (high confidence)

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

If bone metastasis (C79.51 or C79.52) is treated, the medical record must also contain the diagnosis of the primary malignant neoplasm and be available on request.
Medical records must include diagnostic information and lab results that support medical necessity, including documentation of specific signs and symptoms substantiating FDA labeled or off‑label use.
The record should indicate the patient was advised to take adequate calcium and vitamin D supplementation.
Diagnosis codes supporting medical necessity must be submitted on the claim, including breast cancer code plus bone loss code and a code documenting current adjuvant SERM or aromatase inhibitor therapy when applicable.

Intravenous bisphosphonate administration is covered for treatment of osteoporosis when medical record documents need for IV route, including description of treatment failure of oral or self‑administered osteoporosis drugs.
Bisphosphonate therapy is covered for heterotopic ossification when the medical record documents clinical need for treatment and justifies IV administration.
Bisphosphonate therapy is covered for bone metastasis (C79.51 or C79.52) provided the patient's record also contains a diagnosis of the primary malignant neoplasm.
In breast cancer patients receiving adjuvant selective estrogen receptor modulators or aromatase inhibitor therapy, bisphosphonates are covered when billed with an appropriate breast cancer diagnosis code and a bone loss diagnosis code documenting treatment indication.
Intravenous bisphosphonate therapy is covered for osteoporosis when the medical record documents treatment failure of oral or self-administered osteoporosis drugs.
Intravenous bisphosphonate therapy is covered for heterotopic ossification when documented in the medical record supporting medical necessity.

A56907 — Billing and Coding: Bisphosphonate Drug Therapy

J05

A59561 — Billing and Coding: Bisphosphonate Drug Therapy

J05

L34648 — Bisphosphonate Drug Therapy

J05

AETNA-CPB-0753 — Core Decompression for Avascular Necrosis

Ask Verity about documentation requirements, denial risks, or coverage in your state.